Performing meta-analysis with incomplete statistical information in clinical trials

被引:87
|
作者
Ma, Jianbing [1 ]
Liu, Weiru [1 ]
Hunter, Anthony [2 ]
Zhang, Weiya [3 ]
机构
[1] Queens Univ Belfast, Sch Elect Elect Engn & Comp Sci, Belfast BT7 1NN, Antrim, North Ireland
[2] UCL, Dept Comp Sci, London WC1E 6BT, England
[3] City Hosp, Acad Rheumatol Med & Surg Sci, Nottingham NG5 1PB, England
基金
英国工程与自然科学研究理事会;
关键词
D O I
10.1186/1471-2288-8-56
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Results from clinical trials are usually summarized in the form of sampling distributions. When full information (mean, SEM) about these distributions is given, performing meta-analysis is straightforward. However, when some of the sampling distributions only have mean values, a challenging issue is to decide how to use such distributions in meta-analysis. Currently, the most common approaches are either ignoring such trials or for each trial with a missing SEM, finding a similar trial and taking its SEM value as the missing SEM. Both approaches have drawbacks. As an alternative, this paper develops and tests two new methods, the first being the prognostic method and the second being the interval method, to estimate any missing SEMs from a set of sampling distributions with full information. A merging method is also proposed to handle clinical trials with partial information to simulate meta-analysis. Methods: Both of our methods use the assumption that the samples for which the sampling distributions will be merged are randomly selected from the same population. In the prognostic method, we predict the missing SEMs from the given SEMs. In the interval method, we define intervals that we believe will contain the missing SEMs and then we use these intervals in the merging process. Results: Two sets of clinical trials are used to verify our methods. One family of trials is on comparing different drugs for reduction of low density lipprotein cholesterol (LDL) for Type-2 diabetes, and the other is about the effectiveness of drugs for lowering intraocular pressure (IOP). Both methods are shown to be useful for approximating the conventional meta-analysis including trials with incomplete information. For example, the meta-analysis result of Latanoprost versus Timolol on IOP reduction for six months provided in [1] was 5.05 +/- 1.15 (Mean +/- SEM) with full information. If the last trial in this study is assumed to be with partial information, the traditional analysis method for dealing with incomplete information that ignores this trial would give 6.49 +/- 1.36 while our prognostic method gives 5.02 +/- 1.15, and our interval method provides two intervals as Mean epsilon [4.25, 5.63] and SEM epsilon [1.01, 1.24]. Conclusion: Both the prognostic and the interval methods are useful alternatives for dealing with missing data in meta-analysis. We recommend clinicians to use the prognostic method to predict the missing SEMs in order to perform meta-analysis and the interval method for obtaining a more cautious result.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Pentoxifylline in Heart Failure: A Meta-Analysis of Clinical Trials
    Champion, Sebastien
    Lapidus, Nathanael
    Cherie, Godefroy
    Spagnoli, Vincent
    Oliary, Juliette
    Solal, Alain Cohen
    [J]. CARDIOVASCULAR THERAPEUTICS, 2014, 32 (04) : 159 - 162
  • [42] Meta-analysis of 5 Photodisinfection Clinical Trials for Periodontitis
    Andersen, Roger C.
    Loebel, Nicolas G.
    Andersen, Dane M.
    [J]. 12TH WORLD CONGRESS OF THE INTERNATIONAL PHOTODYNAMIC ASSOCIATION: PHOTODYNAMIC THERAPY: BACK TO THE FUTURE, 2009, 7380
  • [43] Propofol and survival: a meta-analysis of randomized clinical trials
    Pasin, L.
    Landoni, G.
    Cabrini, L.
    Borghi, G.
    Taddeo, D.
    Saleh, O.
    Greco, T.
    Monti, G.
    Chiesa, R.
    Zangrillo, A.
    [J]. ACTA ANAESTHESIOLOGICA SCANDINAVICA, 2015, 59 (01) : 17 - 24
  • [44] Clinical outcomes in statin treatment trials - A meta-analysis
    Ross, SD
    Allen, IE
    Connelly, JE
    Korenblat, BM
    Smith, ME
    Bishop, D
    Luo, D
    [J]. ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (15) : 1793 - 1802
  • [45] Meta-analysis in the design and monitoring of clinical trials - Discussion
    Freedman
    Simon
    Pocock
    DerSimonian
    Brown
    DeMets
    Louis
    Chalmers
    Collins
    Clemens
    George
    Feinstein
    Ellenberg
    Olkin
    [J]. STATISTICS IN MEDICINE, 1996, 15 (12) : 1249 - 1252
  • [46] Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials
    Fernandes, Jose Francisco
    Lell, Bertrand
    Agnandji, Selidji Todagbe
    Obiang, Regis Maurin
    Bassat, Quique
    Kremsner, Peter Gottfried
    Mordmueller, Benjamin
    Grobusch, Martin Peter
    [J]. FUTURE MICROBIOLOGY, 2015, 10 (08) : 1375 - 1390
  • [47] Nut intake and adiposity: meta-analysis of clinical trials
    Flores-Mateo, Gemma
    Rojas-Rueda, David
    Basora, Josep
    Ros, Emilio
    Salas-Salvado, Jordi
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2013, 97 (06): : 1346 - 1355
  • [48] A subgroup meta-analysis of multiple sclerosis clinical trials
    Signori, A.
    Sormani, M. P.
    [J]. JOURNAL OF NEUROLOGY, 2014, 261 : S20 - S21
  • [49] Recurrent events in meta-analysis of multiple clinical trials
    Wang, Y
    Flather, M
    Yusuf, S
    Wang, YH
    Li, LX
    Wang, ZC
    [J]. ACTA PHARMACOLOGICA SINICA, 1999, 20 (06): : 495 - 499
  • [50] Clinical trials and a meta-analysis of the effects of vitamins - Reply
    Bleys, Joachim
    Miller, Edgar R.
    Appel, Lawrence J.
    Guallar, Eliseo
    [J]. AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (05): : 1435 - 1436